| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 189,303 | 188,127 |
| Net decrease in cash, cash equivalents, and restricted cash | -18,899 | 58,670 |
| Cash and cash equivalents at beginning of period | 82,187 | - |
| Cash and cash equivalents at end of period | 63,288 | - |
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)